5247742025-04-012025-06-305247742025-04-012025-06-30in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares524774NGLFINENOTLISTEDINE887E01022NGL FINE-CHEM LIMITEDMain BoardEquity2025-04-012026-03-312025-08-012025-07-22INRLakhsQuarterlyFirst quarterSingle segmentPHARMACEUTICALS2025-08-0118:00:002025-08-0119:45:00Not applicablefalsefalseThere is no default on loans and there are no Debt Securities2025-04-012025-06-30UnauditedStandalone1008581000655340001074115000550691000-40519000014470000012083000344680002755450009769680009714700009714700071880001351800020706000076441000000076441000-24110007403000030890000512.3712.370012.3712.37Notes: <BR> 1 The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday 1st August 2025. These results were subjected to Limited Review by the Statutory Auditors of the Company <BR> 2 The above financial results have been prepared in accordance with the Companies Indian Accounting Standards Rules 2015 IndAS prescribed under Section 133 of the Companies Act 2013 and read with the rules framed thereunder and Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended from time to time <BR> 3 The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with INDAS 108 Operating Segment notified pursuant to Companies Indian Accounting Standards Rule 2015 <BR> 4 Previous period figures have been regrouped/rearranged wherever necessary <BR> 5 The figures for the quarter ended March 31 2025 are the balancing figures between the audited figures in respect of the full year ended March 31 2025 and the published year to date figures upto the third quarter ended December 31 2024 of the relevant financial year. <BR> Other Expenses2755450003222000-811000-2411000